MannKind (NASDAQ:MNKD) Announces Earnings Results, Misses Estimates By $0.03 EPS

MannKind (NASDAQ:MNKD - Get Free Report) announced its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.03), Zacks reports. The company had revenue of $90.17 million during the quarter, compared to the consensus estimate of $105.38 million. MannKind had a negative net margin of 6.63% and a negative return on equity of 11.21%. The business's quarterly revenue was up 15.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.04 EPS.

Here are the key takeaways from MannKind's conference call:

• United Therapeutics collaboration expanded — MannKind unveiled MNKD-1501 as ralinepag DPI, received $5M upfront, can earn up to $35M in milestones (about $15M expected in 12 months) plus a 10% royalty, and was confirmed as sole manufacturer of Tyvaso DPI with contractual minimums.
• FUROSCIX momentum and guidance — Q1 net sales for FUROSCIX were $15.5M with doses dispensed up ~64% YoY, record prescribers, and management reaffirmed 2026 FUROSCIX revenue guidance of $110M–$120M.
• Near-term regulatory catalysts — Two PDUFA events (Afrezza Pediatrics on May 29 and FUROSCIX ReadyFlow auto‑injector on July 26) could materially expand addressable markets and adoption if approved.
• MNKD‑201 (nintedanib DPI) advancing — Cohort 1 of the phase I‑B InFlow study in IPF patients is complete with no discontinuations for cough or serious AEs, top‑line data expected in Q3, and global phase II enrollment has started.
• Q1 profitability pressure — Company reported a GAAP net loss of $16.6M (non‑GAAP loss $6.9M) driven by increased R&D and commercial investments for the planned launches and scPharmaceuticals integration, though management says liquidity is sufficient.

MannKind Trading Up 0.6%

NASDAQ:MNKD opened at $3.55 on Thursday. MannKind has a twelve month low of $2.23 and a twelve month high of $6.51. The company has a 50-day moving average of $2.83 and a 200-day moving average of $4.37. The firm has a market cap of $1.10 billion, a price-to-earnings ratio of -50.71 and a beta of 1.04.

Insider Activity at MannKind

In related news, Director Steven B. Binder sold 16,940 shares of the business's stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $3.29, for a total value of $55,732.60. Following the sale, the director directly owned 808,008 shares in the company, valued at $2,658,346.32. The trade was a 2.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Michael Castagna bought 100,000 shares of the business's stock in a transaction that occurred on Tuesday, March 10th. The shares were acquired at an average cost of $2.59 per share, with a total value of $259,000.00. Following the completion of the purchase, the chief executive officer owned 2,575,911 shares of the company's stock, valued at approximately $6,671,609.49. The trade was a 4.04% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 2.60% of the company's stock.

Institutional Investors Weigh In On MannKind

Several large investors have recently modified their holdings of MNKD. Caitong International Asset Management Co. Ltd grew its holdings in shares of MannKind by 108.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,636 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 2,927 shares during the last quarter. Lido Advisors LLC purchased a new stake in shares of MannKind during the fourth quarter valued at $63,000. Mercer Global Advisors Inc. ADV acquired a new position in shares of MannKind in the 4th quarter valued at $70,000. Freestone Grove Partners LP acquired a new position in shares of MannKind in the 4th quarter valued at $80,000. Finally, Ameriprise Financial Inc. boosted its position in shares of MannKind by 45.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 17,055 shares of the biopharmaceutical company's stock valued at $92,000 after purchasing an additional 5,300 shares during the period. 49.55% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Wedbush reduced their price target on shares of MannKind from $10.00 to $8.00 and set an "outperform" rating for the company in a research note on Thursday, March 5th. Zacks Research upgraded shares of MannKind from a "strong sell" rating to a "hold" rating in a research note on Wednesday, April 15th. Royal Bank Of Canada boosted their target price on MannKind from $3.50 to $4.75 and gave the stock a "sector perform" rating in a report on Thursday, May 7th. Mizuho cut their target price on MannKind from $8.00 to $7.00 and set an "outperform" rating for the company in a research report on Thursday, May 7th. Finally, HC Wainwright increased their price target on MannKind from $8.00 to $10.00 and gave the company a "buy" rating in a research note on Thursday, May 7th. Seven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $8.84.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).